Antibodies
Login
Search   
LEAF™ Purified anti-human IL-13 Antibody
LEAF™ Purified anti-human IL-13 Antibody
501909 50 µg ¥22,000     
501910 500 µg ¥60,000     

Product Details

Clone: JES10-5A2
Isotype: Rat IgG1, κ
Isotype Control:LEAF™ Purified Rat IgG1, κ Isotype Ctrl
Reactivity: Human
Immunogen: COS-expressed, recombinant human IL-13
Formulation: Phosphate-buffered solution, pH 7.2, containing no preservative. 0.2 μm filter sterilized. Endotoxin level is < 0.1 EU/μg of the protein (< 0.01 ng/μg of the protein) as determined by the LAL test.
Preparation: The LEAF™ (Low Endotoxin, Azide-Free) antibody was Purified by affinity chromatography.
Concentration: 1.0 mg/ml
Storage & Handling: The antibody solution should be stored undiluted at 4 °C. This LEAF™ solution contains no preservative; handle under aseptic conditions.
Application:

ELISA Capture, ELISPOT Capture - Quality tested
Neut, ICFC, IHC, WB - Reported in the literature

Recommended Usage:

Each lot of this antibody is quality control tested by ELISA analysis. For ELISA applications, a concentration range of 1-4 µg/ml is recommended. To obtain a linear standard curve, serial dilutions of human IL-13 recombinant protein ranging from 2000 to 8 pg/ml are recommended for each ELISA plate. It is recommended that the reagent be titrated for optimal performance for each application.

COA:
Enter Lot#:   
Application
Notes:

ELISA or ELISPOT Capture1,2: The Purified JES10-5A2 antibody is useful as the capture antibody in a sandwich ELISA or ELISPOT assay, when used in conjunction with the biotinylated Poly5020 antibody (Cat. No. 502001) as the detecting antibody. The LEAF™ Purified antibody is suggested for ELISPOT capture.

Application
References:

1. McKenzie, A., et al. 1994. Curr. Prot. Immunol.. John Wiley & Sons. New York. Section 6.18.
2. Abrams, J. 1995. Curr. Prot. Immunol.. John Wiley and Sons, New York. Unit 6.20.
3. Schaerli, P., et al. 2000. J. Exp. Med. 192:1553.
4. Andersson, J., et al. 1994. Immunology 83:16.
5. Skansen-Saphir, U., et al. 1994. Eur. J. Immunol. 24:916.
6. Andersson, U., et al. 1999. Detection and quantification of gene expression. New York:Springer-Verlag.
7. Gelfand, E. W., et al. 2006. J. Aller. and Clinic. Immunol. 117:577.
8. Knorr, C., et al. 1999. Am. J. Pathol. 155:2019.




Compare all formats



Description:

IL-13 is an immunoregulatory cytokine produced primarily by activated Th2 lymphocytes. IL-13 shares 30% amino acid sequence homology with IL-4 and demonstrates similar biological activities. The biological activities of IL-13 include: suppression of macrophage cytotoxic activity, upregulation of IL-1RA expression, and suppression of proinflammatory cytokine secretion. The JES10-5A2 antibody reacts with human interleukin-13 (IL-13). The JES10-5A2 antibody can neutralize the bioactivity of natural or recombinant IL-13.

Other Names: Interleukin-13, NC30
Structure: Cytokine; 17 kD (Mammalian)
Regulation: IL-13Rα2 possible antagonist
Cellular Sources: Activated T cells, mast cells, NK cells
Cellular Targets: B cells, monocytes, macrophages, basophils
Receptors: Moderate affinity IL-13Rα1; high affinity heterodimer IL-13Rα1/IL-4Rα also binds IL-4; both receptor complexes have γ-subunit in common with IL-2R, IL-4R, IL-7R, IL-15R ; high affinity IL-13Rα2 incapable of signaling
Bioactivity/Activities: Suppression of macrophage cytotoxic activity; upregulation of IL-1RA expression; suppression of IL-1, IL-6, IL-8, IL-10, IL-12, chemokines MCP, MIP-1; differentiation of B cells, monocytes
Antigen
References:

1. Fitzgerald, K., et al. Eds. 2001. The Cytokine FactsBook. Academic Press, San Diego.
2. Hilton, D., et al. 1996. P. Natl. Acad. Sci. USA 93:497.
3. Obiri, N., et al. 1995. J. Biol. Chem. 270:8797.
4. Ochensberger, B., et al. 1996. Blood 88:3028.

GeneID: 3596
Latest Publications: View the latest IL-13 articles on HighwirePress.com
UniProt: View information about IL-13 on UniProt.org
Keywords: LEAF™ Purified anti-human IL-13, JES10-5A2, LEAF™, Interleukin-13, NC30, Human, Immunology, Antibodies
Related Products

DescriptionCloneApplications
LEAF™ Purified Rat IgG1, κ Isotype CtrlRTK2071FC, ICFC, WB, IP, ICC, IF, IHC, FA

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/terms). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.
x
Compare Data Across All Formats
This data display is provided for general comparisons between formats. Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors. If you need assistance with selecting the best format contact our expert technical support team.

  • APC anti-human IL-13
    Enriched human CD4+ T cells

    Enriched human CD4+ T cells were stimulated with PMA+ionomycin, then surface stained with CD4 PE/Cy5 and intracellular stained with APC rat IgG1,k isotype control (top) or APC JES10-5A2 (bottom)





  • LEAF™ Purified anti-human IL-13




  • PE anti-human IL-13
    PMA+ionomycin-stimulated T lymphocytes intracellularly stained

    PMA+ionomycin-stimulated T lymphocytes intracellularly stained with JES10-5A2 PE and CD4 (RPA-T4) APC

  • Purified anti-human IL-13




  • PerCP/Cy5.5 anti-human IL-13
    PMA-restimulated Th2 polarized human peripheral

    PMA-restimulated Th2 polarized human peripheral blood lymphocytes intracellular stained with CD3 FITC and JES10-5A2 PerCP/Cy5.5

x
Copyright © 2012 BioLegend, Inc. All rights reserved.